You are here

VALA SCIENCES, INC.

Company Information
Address
VALA SCIENCES, INC.
SAN DIEGO, CA 92121-3212
United States


http://www.valasciences.com

Information

UEI: CZZJVX2BKJF3

# of Employees: 22


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    Amount: $1,056,800.00

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) ...

    STTRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons,-Microglia, and-Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo and HIV ARTs)

    Amount: $565,745.00

    Neurotoxicity is among the most common reasons for failure of drugs during clinical trials, illustrating that current preclinical test models, which feature whole animals or animal cells are extremely ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  3. The Pain in a Dish Assay (PIDA): a high throughput system featuring human stem cell-derived nociceptors and dorsal horn neurons to test compounds for analgesic activity

    Amount: $350,064.00

    Pain causes widespread human suffering and loss of productivity across society. Opioids, widely prescribed to treat pain, are addictive, leading to a national surge in drug abuse and deaths resulting ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  4. The hCNS-HIV/ARV assay system, a platform utilizing human iPSC-neurons/-microglia/-astrocytes to test HIV/AIDS therapeutics for neurotoxicity related to HIV-associated cognitive disroder (HAND)

    Amount: $1,916,189.00

    Globally, about 40 million people live with HIV/AIDS, and HIV antiretroviral agents (ARVs) are a multi-billion dollar pharmaceutical sector with continued development of agents. Thanks to combination ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  5. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    Amount: $299,871.00

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) ...

    STTRPhase I2021Department of Health and Human Services National Institutes of Health
  6. TOPIC 382- THE MICROSCOPIC IMAGING OF EPIGENETIC LANDSCAPE BREAST TUMOR DIFFERENTIATION (MIEL-BTD) ASSAY: A HIGH THROUGHPUT SCREEN TO IDENTIFY NOVEL THERAPEUTICS FOR BREAST CANCER.

    Amount: $299,923.00

    Breast cancer is a deadly disease in modern society with limited therapeutics optionsTumor malignancy is likely due to tumor initiating cells that are relatively undifferentiatedThis project will deve ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  7. The Stem Cell-Derived Muscle Function Assay: A High Throughput Screening Platform Utilizing Kinetic Image Cytometry to Discover Therapeutics for Duchenne Muscular Dystrophy

    Amount: $225,000.00

    Duchenne Muscular DystrophyDMDis an early onsetprogressiveand inevitably fatal disease affectingmalescaused by mutations in the DMD geneX chromosomethat prevent expression of dystrophinDysThere is no ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  8. The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effects

    Amount: $300,000.00

    Neurodevelopmental diseasesNDDsAutism Spectrum DisorderASDIntellectual DisabilitiesBipolar disordersand Schizophreniaetcare prevalent and due to errors in neurodifferentiation and neurocircuitryWhile ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  9. Assay of chemicals for Parkinson's toxicity in human iPSC-derived neurons

    Amount: $2,008,017.00

    Parkinson s DiseasePDafflictsof humans and prevalence increases with ageInitial symptoms include tremors in extremitiesbut PD progresses over yearsaffecting additional limbswith impairment of mood beh ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  10. The Alzheimer's Therapeutics Screening Assay: a high-throughput drug-discovery platform utilizing neurons and microglia derived from human induced pluripotent stem cells and Kinetic Image Cytometry

    Amount: $301,078.00

    Alzheimer s DiseaseADthe most common cause of dementiaincreases with ageafflictsmillion people in the USand there is no cureThis phase I project will initiate development of the Alzheimer s Therapeuti ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government